Pembrolizumab, Paclitaxel, and Bevacizumab for Triple-Negative Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of the immunotherapy drug pembrolizumab, the chemotherapy paclitaxel, and possibly the targeted drug bevacizumab for people with triple-negative breast cancer that has returned after treatment. It aims to see if adding bevacizumab improves outcomes for patients whose tumors are PD-L1 positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with invasive breast cancer.
- Your breast cancer is triple-negative (ER-negative, HER2-negative, PgR can be positive or negative).
- Your tumor is PD-L1 positive (tested on a biopsy or surgical sample).
- You have had 0 or 1 prior chemotherapy for cancer that has come back, and you have not had paclitaxel or bevacizumab for that recurrence.
- You received immunotherapy (like pembrolizumab) before or after surgery for breast cancer, and your cancer returned after that treatment.
- You are in good enough health to be up and about (ECOG score 0 or 1), and you do not have untreated brain metastases, a second active cancer, or a history of lung inflammation that needed steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
This trial tests a new combination of an immunotherapy drug (camrelizumab) with chemotherapy (nab-paclitaxel) and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests whether adding more treatment after surgery can help people with triple-negative breast cancer who still have cancer cells left after initial chemotherapy and immunotherapy. It aims to reduce the chance of cancer coming back.
Hear when a new Recurrent Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.